Gabify has raised $175K in a pre-seed round. This round was led by Inflection Point Ventures. It is a major milestone for the young company since it is aimed at filling critical gaps in speech and developmental therapy. Besides the main investment by Inflection Point Ventures, the startup has also received a grant of ₹25 lakh under the Nidhi Seed Support Scheme by GHRTBI.
This combination of venture funds and institutional financing can set the company on the path to a quicker mission to deliver technology-based health solutions.
Fund allocation and mission of Gabify
The new funds obtained are to be allocated to various sectors that are critical to the growth and expansion of the operations of the startup. One of the primary focuses of Gabify will be on clinical validation to ensure that the technological interventions meet high medical standards. The funds will be used to support the development of technology, improving its main platform. The expansion of the team is also a priority because the company seeks to attract specialized talent to drive its innovation.
Gabify has the mission to offer technology-driven health solutions for early screening and therapy management of speech and neurodevelopmental disorders, including autism and ADHD. The startup is intended to transform neurodevelopmental care with the help of an AI-based platform that will analyze voice and vision to evaluate behavioral indicators. At the heart of its mission lies a bold objective to increase its reach in terms of business and social models, such as B2B, B2C, and CSR-driven models, to transform the lives of one million children by the year 2028.
AI-powered innovation and recognition
Sahil Chopra, Prachi Sood, and Vasyl Leshchuk founded Gabify in 2023. Gabify was founded with the aim of developing an advanced AI-based platform. The startup is dedicated to the initial diagnosis and the treatment management of speech and neurodevelopmental conditions, such as autism and ADHD. Their novelity focuses on a dual AI system that combines voice and vision analysis.
The technology can be used to evaluate various behavioral cues, including speech patterns and facial expressions. It uses clinically validated parameters. Gabify guarantees that its clinical validations are accurate and reliable to its users by integrating automated analysis with a human-in-the-loop approach.
Although it is a relatively new company in the market, Gabify has already shown strong momentum and viable use of its technology. The startup has been able to pilot its platform to a network of over 35 preschools and day care centers. Various institutions such as schools, hospitals, and specialized clinics are already using its tools. The popularity of this usage highlights the need to have more convenient screening tools in the neuro-developmental space.
Conclusion
The funding led by Inflection Point Ventures is a turning point for the journey of Gabify. By having a well-defined plan of clinical validation and technological advancement, Gabify stands a strong chance of filling the gap in the diagnosis and therapy management of children with early diagnosis.
The startup is creating an essential niche within the healthcare ecosystem by taking advantage of a dual AI system and ensuring a dedication to clinical rigor due to human oversight.
Read the full article here